Therapeutic use of CCR5 antagonists is supported by strong expression of CCR5 on CD8(+) T cells in progressive multifocal leukoencephalopathy-associated immune reconstitution inflammatory syndrome

Acta Neuropathol. 2015 Mar;129(3):463-5. doi: 10.1007/s00401-015-1383-6. Epub 2015 Jan 15.

Authors

Guillaume Martin-Blondel¹, Jan Bauer, Emmanuelle Uro-Coste, Damien Biotti, Delphine Averseng-Peaureaux, Nelly Fabre, Hervé Dumas, Fabrice Bonneville, Hans Lassmann, Bruno Marchou, Roland S Liblau, David Brassat

Affiliation

¹ Department of Infectious and Tropical Diseases, Toulouse University Hospital, Toulouse, France, [email protected].

PMID: 25589222
DOI: 10.1007/s00401-015-1383-6

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Anti-Retroviral Agents / therapeutic use
CCR5 Receptor Antagonists / therapeutic use*
CD8-Positive T-Lymphocytes / metabolism*
Cyclohexanes / therapeutic use*
HIV Infections / drug therapy
Humans
Immune Reconstitution Inflammatory Syndrome / drug therapy*
Immune Reconstitution Inflammatory Syndrome / metabolism
Leukoencephalopathy, Progressive Multifocal / drug therapy*
Leukoencephalopathy, Progressive Multifocal / immunology
Leukoencephalopathy, Progressive Multifocal / metabolism
Maraviroc
Microscopy, Confocal
Receptors, CCR5 / analysis
Receptors, CCR5 / biosynthesis*
Triazoles / therapeutic use*

Substances

Anti-Retroviral Agents
CCR5 Receptor Antagonists
CCR5 protein, human
Cyclohexanes
Receptors, CCR5
Triazoles
Maraviroc